Recombinant chimeric monoclonal antibody to Folate Binding Protein/FBP.
Applications
ELISA, Flow Cytometry
Dilutions
ELISA: 1:5,000-10,000, Flow Cytometry: 1:100
Reactivity
Human
Host
Chimeric
Clonality
Monoclonal
Isotype
IgG1
Conjugate
Unconjugated
Purification
Affinity chromatography.
Concentration
Reconstitution dependent.
Product Form
Lyophilized
Reconstitution
Reconstitute with distilled sterile water.
Formulation
Lyophilized from sterile Phosphate Buffered Saline, pH 7.4. Normally 5%-8% Trehalose is added as protectants before lyophilization.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
General Notes
Prior to reconstitution, centrifuge the vial at 5,000g for 3-5 minutes at room temperature. Reconstitute with appropriate volume of distilled sterile water to bring product to 1mg/ml concentration. After addition of distilled sterile water, mix by gentle tapping. Note: It is not recommended to vortex or vigorously pipette the sample.
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
FOLR1 protein is highly expressed on the surface of Expi293 cell membrane. Flow cytometry analysis with 1µg/ml Mirvetuximab Biosimilar - Anti-Folate Binding Protein/FBP Antibody - BSA and Azide free (A324683) on Expi293 cells transfected with human FOLR1 (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram), andIsotype antibody on Expi293 transfected with irrelevant protein (Orange histogram).
ELISA plates were pre-coated with Recombinant Human Folate Binding Protein/FBP Protein (6×His Tag) (A318287) at 2 µg/ml (100 µl/well) which can bind Mirvetuximab Biosimilar - Anti-Folate Binding Protein/FBP Antibody - BSA and Azide free (A324683) in a linear range of 0.64-16 ng/ml.
Publishing research using Mirvetuximab Biosimilar - Anti-Folate Binding Protein/FBP Antibody - BSA and Azide free (A324683)? Please let us know so that we can list the citation on this page.
